| pubmed-article:17045207 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17045207 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:17045207 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:17045207 | lifeskim:mentions | umls-concept:C0162638 | lld:lifeskim |
| pubmed-article:17045207 | lifeskim:mentions | umls-concept:C0376545 | lld:lifeskim |
| pubmed-article:17045207 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:17045207 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:17045207 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:17045207 | pubmed:dateCreated | 2006-10-18 | lld:pubmed |
| pubmed-article:17045207 | pubmed:abstractText | We discovered that monoclonal antibodies (mAbs) specific to human beta(2)-microglobulin (beta(2)M) induce apoptosis in vitro and were therapeutic in mouse models of myeloma and other hematological tumor cells. Cell death occurred rapidly, without the need for exogenous immunological effector mechanisms. The mAbs induced cell death via recruiting MHC class I molecules to lipid rafts and activating Lyn and PLCgamma2, leading to activated JNK and inhibited PI3K/Akt and ERK, compromised mitochondrial integrity, and caspase-9-dependent cascade activation. Although the expression of beta(2)M on normal hematopoietic cells is a potential safety concern, the mAbs were selective to tumor-transformed cells and did not induce apoptosis of normal cells. Therefore, such mAbs offer the potential for a therapeutic approach to hematological malignancies. | lld:pubmed |
| pubmed-article:17045207 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17045207 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17045207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17045207 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17045207 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:17045207 | pubmed:issn | 1535-6108 | lld:pubmed |
| pubmed-article:17045207 | pubmed:author | pubmed-author:DayJ OJO | lld:pubmed |
| pubmed-article:17045207 | pubmed:author | pubmed-author:YangJingJ | lld:pubmed |
| pubmed-article:17045207 | pubmed:author | pubmed-author:WangMichaelM | lld:pubmed |
| pubmed-article:17045207 | pubmed:author | pubmed-author:BarlogieBartB | lld:pubmed |
| pubmed-article:17045207 | pubmed:author | pubmed-author:YaccobyShmuel... | lld:pubmed |
| pubmed-article:17045207 | pubmed:author | pubmed-author:YiQingQ | lld:pubmed |
| pubmed-article:17045207 | pubmed:author | pubmed-author:KwakLarry WLW | lld:pubmed |
| pubmed-article:17045207 | pubmed:author | pubmed-author:WezemanMichel... | lld:pubmed |
| pubmed-article:17045207 | pubmed:author | pubmed-author:QianJianfeiJ | lld:pubmed |
| pubmed-article:17045207 | pubmed:author | pubmed-author:WangSiqingS | lld:pubmed |
| pubmed-article:17045207 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17045207 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:17045207 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17045207 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17045207 | pubmed:pagination | 295-307 | lld:pubmed |
| pubmed-article:17045207 | pubmed:dateRevised | 2011-11-2 | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:meshHeading | pubmed-meshheading:17045207... | lld:pubmed |
| pubmed-article:17045207 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:17045207 | pubmed:articleTitle | Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. | lld:pubmed |
| pubmed-article:17045207 | pubmed:affiliation | Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. | lld:pubmed |
| pubmed-article:17045207 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17045207 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:17045207 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17045207 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17045207 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17045207 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17045207 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17045207 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17045207 | lld:pubmed |
